Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.

Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A
Clin Cancer Res. 2020 26 (14): 3803-3818

PMID: 32234759 · PMCID: PMC7367743 · DOI:10.1158/1078-0432.CCR-19-1895

MeSH Terms (22)

Adult Aged Animals Antineoplastic Combined Chemotherapy Protocols Cell Line, Tumor Female Humans Male MAP Kinase Signaling System Melanoma Mice Middle Aged Mitogen-Activated Protein Kinase Kinases Mutation Protein Kinase Inhibitors Proteolysis Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins c-mdm2 Skin Neoplasms Tumor Suppressor Protein p53 Ubiquitination Xenograft Model Antitumor Assays

Connections (1)

This publication is referenced by other Labnodes entities: